Intraperitoneal recombinant interferon gamma in ovarian cancer patients with residual disease at second-look laparotomy.
about
rIFN-gamma-mediated growth suppression of platinum-sensitive and -resistant ovarian tumor cell lines not dependent upon arginase inhibitionThe interaction of anticancer therapies with tumor-associated macrophagesChimeric NKG2D T cells require both T cell- and host-derived cytokine secretion and perforin expression to increase tumor antigen presentation and systemic immunity.Chimeric NKG2D expressing T cells eliminate immunosuppression and activate immunity within the ovarian tumor microenvironmentOvarian cancer immunotherapy: opportunities, progresses and challengesIntraperitoneal macrophages and tumor immunity: A review.Cytokines, GM-CSF and IFNgamma administered by priming and post-chemotherapy cycling in recurrent ovarian cancer patients receiving carboplatin.A phase II study of GM-CSF and rIFN-gamma1b plus carboplatin for the treatment of recurrent, platinum-sensitive ovarian, fallopian tube and primary peritoneal cancer.The emergence of immunomodulation: combinatorial immunochemotherapy opportunities for the next decade.Immunotherapy for ovarian cancer.Tumor-cell co-culture induced alternative activation of macrophages is modulated by interferons in vitro.Monocyte and interferon based therapy for the treatment of ovarian cancer.Immunotherapy for gynaecological malignancies.Interferon signaling in ascites-associated macrophages is linked to a favorable clinical outcome in a subgroup of ovarian carcinoma patients.Cisplatin resistance is associated with reduced interferon-gamma-sensitivity and increased HER-2 expression in cultured ovarian carcinoma cellsPhase II study of intraperitoneal recombinant interleukin-12 (rhIL-12) in patients with peritoneal carcinomatosis (residual disease < 1 cm) associated with ovarian cancer or primary peritoneal carcinoma.Cytotoxic response of ovarian cancer cell lines to IFN-gamma is associated with sustained induction of IRF-1 and p21 mRNA.Interferon-gamma in the first-line therapy of ovarian cancer: a randomized phase III trial.Maintenance treatment with interferon for advanced ovarian cancer: results of the Northern and Yorkshire gynaecology group randomised phase III study.Novel agents in ovarian cancer.Evaluating the role of IL-12 based therapies in ovarian cancer: a review of the literature.Immune therapy for ovarian cancer: promise and pitfalls.Tumour-associated macrophages as treatment targets in oncology.The Unique Molecular and Cellular Microenvironment of Ovarian CancerPhase II trial of ifosfamide and cisplatinum in advanced ovarian cancer.Determination of molecules regulating gene delivery using adenoviral vectors in ovarian carcinomas.Differential expression of cytokine transcripts in human epithelial ovarian carcinoma by solid tumour specimens, peritoneal exudate cells containing tumour, tumour-infiltrating lymphocyte (TIL)-derived T cell lines and established tumour cell lines.The Dark Side of IFN-γ: Its Role in Promoting Cancer Immunoevasion.Natural Killer Cell-Based Immunotherapy in Gynecologic Malignancy: A Review.Interferon regulatory factor-1 mediates interferon-gamma-induced apoptosis in ovarian carcinoma cells.High-dose melphalan-based chemotherapy and autologous stem cell transplantation after second look laparotomy in patients with chemosensitive advanced ovarian carcinoma: long-term results.Oncodriver inhibition and CD4+ Th1 cytokines cooperate through Stat1 activation to induce tumor senescence and apoptosis in HER2+ and triple negative breast cancer: implications for combining immune and targeted therapies.A Phase 1 trial of autologous monocytes stimulated ex vivo with Sylatron (Peginterferon alfa-2b) and Actimmune (Interferon gamma-1b) for intra-peritoneal administration in recurrent ovarian cancer
P2860
Q24805224-72791737-B853-4462-A9C0-BD719E0A40A8Q27016634-001A14C1-1169-4FB8-8113-F29D0ED2CD7AQ33671322-CB6BAEC6-5C1C-4291-90E1-55537958C2CEQ33671344-50B1F36D-5665-4D6B-814E-A8ACFC1B68A4Q33702218-511B4720-B902-436F-87F4-660A777DA801Q34076951-3462BB1B-15BE-48C5-8C6E-137BD0FD674AQ34590873-7AAE5191-6343-459C-B152-3C06C5739931Q34667823-24E87B24-2B9D-4E25-AA2E-623449525C7AQ35058213-8F3BE573-6500-4CCA-98CE-7BB101C0DCF4Q35164189-AEA6E856-FEC2-416D-BD65-06A4E2035CB4Q35872012-20B8B95E-757C-459C-BD32-80E46764D750Q35973378-C44E1E94-FB5B-46E7-A972-025DFAB58DD0Q36239661-99BB9787-F1AF-4E46-B370-F9957CE46841Q36317366-310796D9-D3B9-4A3A-B4C6-E42D239780D2Q36431436-19E15084-6457-44B4-80ED-130FD4B5D0F3Q36470056-E08DE3CE-28E8-41DA-8400-36E1C6AFAB79Q36618050-10134811-7209-40E8-869C-EDFD8D4F6515Q36621312-71183762-A2B4-44C7-B7A0-0C0012BB07B0Q36626046-D6B3EC68-0C1D-4C13-8A58-25D023934F51Q36904860-03EE69B6-A5FD-40CC-8124-C4F1FA31AA5BQ37851520-6A94DE74-72F5-425C-9A6F-584A6C309471Q37873928-0B553BBD-9B77-479A-A930-4BA05BADD9B8Q39100693-F4429B6A-5769-40FC-9B15-3D6EB8B7233CQ39169603-EA865F96-ADA0-499B-A03B-55A1126FD1FEQ43939030-92C4B7D6-9D88-4CDE-A7E1-F9B74AB1864EQ44270897-9F8BBE84-A280-43EE-B9B9-6AFBBEA16245Q47901983-0A39636F-6B76-48C2-AF78-747416145940Q48337458-75E197A3-FF14-4CC7-B477-35E85568587CQ49724715-BD74DFB5-68A0-4954-8EF4-45399428DA39Q53671452-A3CB121F-C2A0-47D1-9844-FBDE3DB1D0D8Q53686001-9BF830C7-65B6-4EC8-81CF-67566694558CQ55010019-CA88FF0E-1EB3-41B6-B531-6F74DFDAA0FFQ56517336-64AB2FA6-76ED-47D7-9DAB-37CEFFA3DF59
P2860
Intraperitoneal recombinant interferon gamma in ovarian cancer patients with residual disease at second-look laparotomy.
description
1996 nî lūn-bûn
@nan
1996年の論文
@ja
1996年論文
@yue
1996年論文
@zh-hant
1996年論文
@zh-hk
1996年論文
@zh-mo
1996年論文
@zh-tw
1996年论文
@wuu
1996年论文
@zh
1996年论文
@zh-cn
name
Intraperitoneal recombinant in ...... ase at second-look laparotomy.
@en
type
label
Intraperitoneal recombinant in ...... ase at second-look laparotomy.
@en
prefLabel
Intraperitoneal recombinant in ...... ase at second-look laparotomy.
@en
P2093
P1476
Intraperitoneal recombinant in ...... ase at second-look laparotomy.
@en
P2093
E François
E Pujade-Lauraine
F Maloisel
J P Guastalla
M Brandely
M Mousseau
P304
P356
10.1200/JCO.1996.14.2.343
P407
P577
1996-02-01T00:00:00Z